chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Enlarged lymph nodes; Pain in abdomen; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), intramuscular, administered in arm, administration date 26Jan2021 11:00 (Lot number: EL3302) at the age of 67 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "NHL Lymphoma", start date: 2013, stop date: 2014, notes: Stop date: 2014 , Pertinent details: Rituxan as tx; "Lyme disease", start date: 2004, stop date: 2004, notes: Stop date: 2004; "Bell's Palsy", start date: 2004, stop date: 2004, notes: Stop date: 2004; "Possible recurrence of lymphoma", start date: 2021 (ongoing), notes: Stop date: Ongoing checked, Pertinent details: still waiting for final diagnosis; "Spinal tap", start date: 2004 (unspecified if ongoing); "colonoscopy", start date: 2013 (unspecified if ongoing), notes: Polyps. Family history included: "Pancreatic cancer" (unspecified if ongoing), notes: Mother: Pancreatic cancer, died 1996 at age 69; "Heart problems" (unspecified if ongoing), notes: Father: Heart problems, died 2015 at 88. The patient's concomitant medications were not reported. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 31Jan2021, outcome "unknown", described as "Enlarged lymph nodes"; ABDOMINAL PAIN (non-serious) with onset 31Jan2021, outcome "unknown", described as "Pain in abdomen". The events "enlarged lymph nodes" and "pain in abdomen" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of lymphadenopathy, abdominal pain.  Additional Information: Vaccination Facility Type was Hospital. No prior vaccination (within 4 weeks).   Follow-Up (14Feb2022): Follow-up attempts are completed. No further information is expected.
On first night, broke out in hives.  Now on day 11 of fevers.  Fevers have gotten as high as 103.7, but usually around 102
Pt experienced arthralgia/myalgia subsequent to receiving the second dose of Havrix, with gradual improvement over 5-7 days.
Date of last mensural period: 12/05/2020. Due date is 9/13/2021. Normal healthy pregnancy. No past medical history other than migraines for patient. Received 1st dose of Pfizer on 04/30/2021. No issues. Received 2nd dose on 5/21/2021. Had fevers, aches, nausea and vomiting for x2 days, all normal vaccine side effects. 4 days later I am diagnosed with gestational diabetes and one week later I am in the ER with high blood pressure of 196/110 and HR of 140. Now being evaluated for preeclampsia.
Bone pain; Body pain; Fatigue; Fever; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (Bone pain), MYALGIA (Body pain), FATIGUE (Fatigue) and PYREXIA (Fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BONE PAIN (Bone pain), MYALGIA (Body pain), FATIGUE (Fatigue) and PYREXIA (Fever). At the time of the report, BONE PAIN (Bone pain), MYALGIA (Body pain), FATIGUE (Fatigue) and PYREXIA (Fever) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment medication was reported.
I received my shot at 3:30 PM on 01/09/21.  I felt very tired on 01/12/21 before that went away that evening.  I began feeling dizzy and nauseus around 8:00 PM Monday, 01/11/21, and again periodically on 01/12/21.  The dizzy and nausea feeling continued consistently throughout 01/12/21 and 01/13/21.  I went to my primary care provider on 01/12/21 who gave me medication to help with nausea and dizziness.  She chalked it up to anxiety.  I became more worried on the evening of 01/13/21 and went to the ER.  The ER doctor stated it could be a reaction to the vaccine, inflammation in the ear/calcium buildup in the ear, or just my anxiety.  I do want to note I was nervous about getting this shot and have a history of having trouble distinguishing between true issues I am having and issues caused by my anxiety.  As of today, 01/15/21, I took Methazine which seems to have helped the dizziness, but not completely.  I am not currently nauseus.
Information has been received from a director of nursing at the facility, concerning a female with respiratory problems who was vaccinated 6 months ago (approximately in May 2009) with a first dose of PNEUMOVAX 23 (route and lot not reported).  It was reported that on 10-NOV-2009, the patient was vaccinated SQ with a second dose of PNEUMOVAX 23 vaccine (lot number: 663935/0528Y, expiration date 26-NOV-2009).  The nurse reported that the patient developed 8 cm and red, hot area at the injection site with in an hour after receiving the vaccine.  No fever noted.  No laboratory tests were performed.  The patient sought medical attention by visit the physician.  At the time of the report the outcome of the patient was unknown.  This is one of several reports received from the same source.  Additional information has been requested.
Treatment of COVID-19; Treatment of COVID-19; Running nose; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 06Feb2021 at 09:00 as dose 1, single (Lot number: EN), in left arm, on 27Feb2021 at 09:00 as dose 2, single (Lot number: EN6201), in left arm and on 29Oct2021 at 15:00 as dose 3 (booster), single (Lot number: 3203080) at the age of 66 years, in left arm for covid-19 immunization. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: RHINORRHOEA (non-serious) with onset 15Jul2022, outcome "unknown", described as "Running nose"; VACCINATION FAILURE (medically significant) with onset 15Jul2022, outcome "unknown", COVID-19 (medically significant) with onset 15Jul2022, outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: Body temperature: (15Jul2022) 102, notes: 15Jul2022 6:30 pm fever 102; (16Jul2022) 101, notes: 15Jul2022 6:15 pm fever 101; (23Jul2022) 100.1, notes: 23Jul2022 temperature 100.1 after shower; (23Jul2022) 98.7, notes: 23Jul2022 temperature 100.1 after shower. Reduce to 98.7 after one hour; SARS-CoV-2 test: (14Jul2022) Negative, notes: 14Jul2022 tired, test negative; (15Jul2022) Positive, notes: 15Jul2022 early morning, running nose, tested positive; (21Jul2022) Negative, notes: 21Jul tested negative, tired and sleep much more than normal. Eyes blurry; (22Jul2022) Negative, notes: 22Jul2022 tested negative; (23Jul2022) Positive, notes: 23Jul2022 tired in the morning. Blurry eyes. Running nose from noontime. Tested positive around 6:30 pm. Therapeutic measures were taken as a result of vaccination failure, covid-19, rhinorrhoea.  Clinical course: Other medication in 2 weeks was yes. Treatment AE was No. Known allergies was No. Other medical history was No. 14Jul2022 tired, test negative 15Jul2022 early morning, running nose, tested positive. 15Jul2022 2:00 pm took first dose of Paxlovid. 15Jul2022 6:30 pm fever 102, took Tylenol, sweat and fever reduced.
ROUGHLY 7-8 HOURS AFTER RECEIVING THE SECOND COVID VACCINE, PALPITATIONS AND SLIGHT SHORTNESS OF BREATH WAS EXPERIENCED.   FELT FLUTTERING OFF AND ON.  ON 3/17 WENT TO ED AND FOUND TO BE IN AFLUTTER RVR.  HISTORY OF IRREGULARITY WITH MEDICAL AND SURGICAL INTERVENTIONS.
Anaphylaxis shock, skin discoloration (redness); shortness of breath. Patient began taking KEFLEX an hour before anaphylaxis shock also.
Pain and tenderness at site of injection, improved over the following several days but did not resolve. Presented for f/u appointment 12/1/15, dx with bursitis of right shoulder.
1/6/22  Sign symptoms as above  -pt c/o    Nasal congestion,  clear runny nose   ,       , low-grade    Fever,cough, bodyache ,for last  4   Days   Patient states she  Doesn;t work/ patient  States she stays home     Patient denies  recent traveling.  Patient denies change in smell.or taste  Pt states her son has covid- day 6 -they  don;t live togather but he brought her today  Here  at icc for dr's appt       Patient denies associated abd pain.-no abd pain at all  Per pt /  No nausea no vomiting no diarrhea. .pt denies eating left over food  /pt states   no one    sick   In family  is sick with with same s/s.  Patient denies  recent traveling .  No UTI signs symptoms    Patient denies associated   St,  1/6/22  Review of Systems  =================== Constitutional:        low grade fever+, Patient had low-grade fever in the beginning but no more now. no recent   Unexpected wt loss ,no night sweats        Headache +  Patient denies headache patient denies  bodyache   Patient complains of body ache      HEENT: Negative for ear pain  postnasal drip,sore throat,    Patient complains of stopped up nose/,  rhinorrhea, sneezing, +  No change in smell no change in taste.   Eyes: Negative for photophobia, pain, redness  ,no visual disturbance. No eye drainage  Respiratory   -patient denies shortness of breath    No pleuritic chest pain.      Cough   +small dry    negative for  Wheezing     Cardiovascular: Negative for chest pain, palpitations     Gastrointestinal: Negative for , nausea, vomiting, abdominal pain, diarrhea,  now.     Skin: Negative for  rash. No skin lesions  Neurological: Negative for dizziness no syncope.     Phycological  Stable
Rash 9x7 delayed induration at and below inj site onset 7d after inj Narrative:  NO meds required. 7d delayed onset
Patient possibly inadvertently received 1cc of Moderna COVID vaccine instead of 0.5cc. Patient was notified. State was notified.
pain at the injection site beginning approximately 30 seconds after injection; stiffening of the muscle to the point of immobility beginning 10 minutes after receiving injection lasting for two days; fever (100F) beginning approx. five hours after injection lasting 16 hours; pain in joints (particularly wrists and fingers) beginning approximately two days after injection continuing on and off for 1.5 weeks
Maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma since 1990 and Hypertension since 2010. Concomitant products included ALBUTEROL [SALBUTAMOL] for Asthma, NIFEDIPINE for Hypertension, ASPIRIN [ACETYLSALICYLIC ACID] and ENOXAPARIN SODIUM (LOVENOX [ENOXAPARIN SODIUM]) for Thrombosis.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 22-Aug-2020 and the estimated date of delivery was 29-May-2021. On 05-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  nineteenth week of the pregnancy.  On 05-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Laboratory test: normal (normal) She had routine blood works and tests for pregnancy and the results were normal. On an unknown date, Pregnancy test: positive (Positive) Positive, 6 weeks after the last menstrual period.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient Medical history includes Blood clot .   Treatment information was not reported .  Company Comment: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Patient was administered a full dose of the H1N1 nasal mist vaccine on November 5, 2009.  Patient woke up with a very high fever on 11/13/2009 that wouldn't break with Tylenol (finally it lowered with a cold bath).  He has had a fever over 100 since then (today is 11/16/2009.  He can't stop coughing, is hoarse, extremely congested, has little appetite, and his cheeks are flushed.
Pt had Covid in November 2020. He was in the hospital and had blood clots in the left leg.
Given 0.25ml instead of 0.5ml for second dose.  Pt was contacted on 01/15/2022 and offered another dose of 0.25ml. He declined.  He was told that due to the lesser dose he did not complete the series to be considered fully vaccinated.  He still did not want.
Mom reports "baseball size, red" area on left upper limb; states pt. c/o itching and mild pain at site.
Cellulitis; Nausea; Fatigue; Fever; chills; Headache; A spontaneous report  was received from a consumer concerning a 68-years-old , female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced nausea, fatigue, fever, chills and headache. Sometime after that, the patient was diagnosed with a Cellulitis infection.   The patient's medical history was not  provided by the reporter. Products known to have been used by patient with in past two weeks included, metformin, levothyroxine and refasten.   On 28-JAN-2021 , prior to the onset of the events, the patient received the first of two dose of mRNA-1273 (Lot number: 039K20A) through Intramuscular route for prophylaxis of COVID-19 infection.    On an unspecified date, 2 weeks after vaccination patient experienced nausea, fatigue, fever, chills and headache. Sometime after that, the patient was diagnosed with a Cellulitis infection. Treatment included antibiotics.   Action taken with mRNA-1273 in response to the events was not applicable.   The outcome of the event, nausea, fatigue,fever, chills and headache and cellulitis infection was considered unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous report as received from a pharmacist refers to a patient of unknown age. On 09-NOV-2014 the patient was administered a dose of PNEUMOVAX 23 (strength, dose, frequency, route, lot # and indication were not provided). PNEUMOVAX 23 was exposed to temperatures outside of the proper storage range. No adverse effect reported. No further information was provided. Additional information has been requested.
A non-serious report of high fever, sore throat, and coughing has been received from a consumer concerning a five-year-old female patient. At the time of this report, medical history or concomitant medications were provided. The patient received FluMist on an unknown date. One to two days after the patient received FluMist, the patient developed a high fever, sore throat, and coughing. No outcome for the events was provided by the reporter. The reporter provided no causality assessment for the events. The reporting source of this case is spontaneous, thus the sponsor's comment is not applicable.
Bruising; This a spontaneous report from a contactable consumer (patient). A 59-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number and Expiry date was not reported) via an unspecified route of administration on 31Mar2021 (at the age of 59 years old) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. It was reported that patient takes lot of concomitants but was not reported and stated that patient was not going to sort out her medications right now. On an unspecified date, the patient experienced extreme bruising. It was very unusual for her to bruise like that. No treatment was received. The outcome of the event was unknown.  No follow-up attempts are possible; Information about Lot/Batch number cannot be obtained.
Loud Tinnitus right ear, induced by booster shot.  Doctor states he?s received a spike in Tinnitus cases resulting from vaccines.  This is a huge issue as failure to treat early and recognize cause can result in a permanent dehabilitating  condition.  It has been 2 and a half weeks and no reduction in high level tinnitus screech in right ear.  Significant depression first 2 weeks,  2nd course of steroids being taken.
Report 20010005861 describes left deltoid atrophy (injection site) in a 38 year old female who received hep B vaccine (brand unknown). Allergies and concomitant medications are not specified. The vaccinee experiences depression. In approx. 1997, the vaccinee received her first IM-left deltoid dose of hep B vaccine (brand unknown). Subsequently, in approx. 1997, she developed left deltoid atrophy. The muscle subsequently "came back." On an unspecified date, the vaccinee received her second dose of hep B vaccine (brand unknown). On an unspecified date, the vaccinee received her 3rd IM-gluteal dose of hep B vaccine (brand unknown). The vaccinee experienced continued atrophy of the left deltoid. On examinatiion, the physician noted a 4-5 cm area "dent" on left deltoid, good range of motion, and no pain. Per the physician, the vaccinee has "no" deltoid. Per reporting pharmacist, "possibly the adverse event is not related to the vaccine." As of 01/10/2001, the outcome of the event is ongoing.
Patient received hepatitis B vaccine with no information as to where/exactly when; no manufacturer information, no other information. He came with arm soreness 2 weeks after injection and was told not to get the third injection.
Pt recvd vax & 21JUL92 had elevated liver function tests; reporter indicated that it is unk whether this date was typographical error;
I found out I was pregnant the middle of October between my 1st and 2nd shot.  I was hesitant to get the 2nd shot being so very early in my pregnancy but got it any way.  I suffered a missed miscarriage that was found on December 9th at a little over 12 weeks, gestational age measured approximately 10 weeks 2 days.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. On an unknown dates the patient was vaccinated with the first and second dose of GARDASIL (route and lot number not reported). The medical assistant reported that on an unspecified date the patient received the 3rd dose of GARDASIL (route and lot number not reported) which was 2 years after the patient received the 2nd dose. No adverse effects were reported. Additional information has been requested.
Sinus infection symptoms; Swollen lymph nodes; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of SINUSITIS (Sinus infection symptoms) and LYMPHADENOPATHY (Swollen lymph nodes) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SINUSITIS (Sinus infection symptoms) and LYMPHADENOPATHY (Swollen lymph nodes). At the time of the report, SINUSITIS (Sinus infection symptoms) and LYMPHADENOPATHY (Swollen lymph nodes) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication list was not provided. Treatment information was not provided.
Received vaccine at 3:25. At midnight I began have restless legs, pain in joints and muscles. Headache, diarrhea, chills and fever.
Patient fainted. Was seen by provider and mother was told to watch for other reactions, if any to go to emergency room.
16 week pregnant female received Adacel with no reported adverse event; Initial information regarding an unsolicited valid non-serious case was received from a physician or consumer/non-health care professional via Medical Information (Reference number- 00800971) and transmitted to Sanofi on 06-Oct-2021.   This case involves a 16 week pregnant female received vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (exposure during pregnancy).   Data regarding this pregnancy were received prospectively.  Patient was exposed to the vaccine at gestation period of 16 weeks.  The date of last menstrual period was not reported.  The estimated due date was not reported.  The patient medical history, past medical treatment, family history and concomitant medication were not provided.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  It was the case of vaccine exposure during pregnancy (latency same day). The patient was pregnant when she received ADACEL vaccine.  Additionally, at time of reporting, the outcome of the pregnancy is unknown.  There will be no information available on the batch number for this case.
This case was reported by a nurse via call center representative and described the occurrence of pain in a 60-year-old female patient who received SHINGRIX for prophylaxis. On 25th July 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, several days after receiving SHINGRIX, the patient experienced pain, hip discomfort, walking difficulty, leg discomfort and activities of daily living impaired. On an unknown date, the outcome of the pain, hip discomfort and walking difficulty were not recovered/not resolved and the outcome of the leg discomfort and activities of daily living impaired were unknown. It was unknown if the reporter considered the pain, hip discomfort, walking difficulty, leg discomfort and activities of daily living impaired to be related to SHINGRIX. Additional details were provided as follows: The nurse practitioner stated that she developed terrible pain and had problems in her back, hips, and legs a few days after receiving the SHINGRIX. The adverse events were continuing to get worse and the nurse now is dependent on a cane to help her walk. She was having issues performing her daily activities. In follow up the reporter refered to rheumatology for symptoms  On unknown date, lab tests C-reactive protein rate, Red blood cell sedimentation rate test were elevated and raising, Antinuclear antibody test and Rheumatoid factors were normal. Lab Comments: On unknown date, lab tests CRP rate, SED rate, ANA test and Rheumatoid factors were performed.
body ache same day as nose dose. followed in succesion by runny nose, conjestion, chills, sore throat, worse body aches
Hard lump and swelling and redness at injection site lasting for longer than 2 days. Seen by doctor and advised to take otc allergy medicine
Itchy palms 6 hours after the injection; an hour later: severe head ache, chills, vomiting, diarrhea achy joints.
She received 2nd dose Moderna 18 day follow 1st dose.    Developed chills, nausea, dizziness and "some cough, but not much".    Developed vomiting and headache.   Symptoms improved, but chills, nausea and dizziness persists still.
petechia of lower extremities and trunk, redness of palms and bottom of feet, swelling on hands, sores in the mouth